221 related articles for article (PubMed ID: 32170045)
1. Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders: A prospective study.
Li S; Ren H; Xu Y; Xu T; Zhang Y; Yin H; Zhang W; Li J; Ren X; Fang F; Li W; Zhu Y; Peng B; Wang J; Zhong Y; Cui L
Neurol Neuroimmunol Neuroinflamm; 2020 May; 7(3):. PubMed ID: 32170045
[TBL] [Abstract][Full Text] [Related]
2. Differential efficacy of mycophenolate mofetil in adults with relapsing myelin oligodendrocyte glycoprotein antibody-associated disorders.
Wang M; Zeng P; Du C; Xue H; Cui Z; Zhang H; Jia D; Zhang C
Mult Scler Relat Disord; 2021 Aug; 53():103035. PubMed ID: 34077831
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of rituximab for relapse prevention in myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG)-associated disorders (MOGAD): A systematic review and meta-analysis.
Nepal G; Kharel S; Coghlan MA; Rayamajhi P; Ojha R
J Neuroimmunol; 2022 Mar; 364():577812. PubMed ID: 35063726
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of the effectiveness of relapse prevention therapy for myelin-oligodendrocyte glycoprotein antibody-associated disease.
Chang X; Zhang J; Li S; Wu P; Wang R; Zhang C; Wu Y
Mult Scler Relat Disord; 2023 Apr; 72():104571. PubMed ID: 36905816
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders.
Montcuquet A; Collongues N; Papeix C; Zephir H; Audoin B; Laplaud D; Bourre B; Brochet B; Camdessanche JP; Labauge P; Moreau T; Brassat D; Stankoff B; de Seze J; Vukusic S; Marignier R;
Mult Scler; 2017 Sep; 23(10):1377-1384. PubMed ID: 27885065
[TBL] [Abstract][Full Text] [Related]
6. Factors Associated With Relapse and Treatment of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in the United Kingdom.
Satukijchai C; Mariano R; Messina S; Sa M; Woodhall MR; Robertson NP; Ming L; Wassmer E; Kneen R; Huda S; Jacob A; Blain C; Halfpenny C; Hemingway C; O'Sullivan E; Hobart J; Fisniku LK; Martin R; Dopson R; Cooper SA; Williams V; Waters PJ; Ramdas S; Leite MI; Palace J
JAMA Netw Open; 2022 Jan; 5(1):e2142780. PubMed ID: 35006246
[TBL] [Abstract][Full Text] [Related]
7. Mycophenolate mofetil: An alternative disease-modifying agent for MOG-IgG-associated disorders in childhood: A single-center bidirectional cohort study.
Zhou J; Li J; Ren C; Zhou A; Zhuo X; Gong S; Ding C; Fang F; Zhang W; Ren X
Mult Scler Relat Disord; 2022 Dec; 68():104128. PubMed ID: 36096009
[TBL] [Abstract][Full Text] [Related]
8. Encephalitis is an Important Phenotype of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Diseases: A Single-Center Cohort Study.
Ren C; Zhou A; Zhou J; Zhuo X; Dai L; Tian X; Yang X; Gong S; Ding C; Fang F; Ren X; Zhang W
Pediatr Neurol; 2024 Mar; 152():98-106. PubMed ID: 38242024
[TBL] [Abstract][Full Text] [Related]
9. Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders.
López-Chiriboga AS; Majed M; Fryer J; Dubey D; McKeon A; Flanagan EP; Jitprapaikulsan J; Kothapalli N; Tillema JM; Chen J; Weinshenker B; Wingerchuk D; Sagen J; Gadoth A; Lennon VA; Keegan BM; Lucchinetti C; Pittock SJ
JAMA Neurol; 2018 Nov; 75(11):1355-1363. PubMed ID: 30014148
[TBL] [Abstract][Full Text] [Related]
10. Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
Chen JJ; Huda S; Hacohen Y; Levy M; Lotan I; Wilf-Yarkoni A; Stiebel-Kalish H; Hellmann MA; Sotirchos ES; Henderson AD; Pittock SJ; Bhatti MT; Eggenberger ER; Di Nome M; Kim HJ; Kim SH; Saiz A; Paul F; Dale RC; Ramanathan S; Palace J; Camera V; Leite MI; Lam BL; Bennett JL; Mariotto S; Hodge D; Audoin B; Maillart E; Deschamps R; Pique J; Flanagan EP; Marignier R
JAMA Neurol; 2022 May; 79(5):518-525. PubMed ID: 35377395
[TBL] [Abstract][Full Text] [Related]
11. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder.
Chen JJ; Flanagan EP; Bhatti MT; Jitprapaikulsan J; Dubey D; Lopez Chiriboga ASS; Fryer JP; Weinshenker BG; McKeon A; Tillema JM; Lennon VA; Lucchinetti CF; Kunchok A; McClelland CM; Lee MS; Bennett JL; Pelak VS; Van Stavern G; Adesina OO; Eggenberger ER; Acierno MD; Wingerchuk DM; Lam BL; Moss H; Beres S; Gilbert AL; Shah V; Armstrong G; Heidary G; Cestari DM; Stiebel-Kalish H; Pittock SJ
Neurology; 2020 Jul; 95(2):e111-e120. PubMed ID: 32554760
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and tolerability of different therapies in preventive treatment of MOG-IgG-associated disorder: A network meta-analysis.
Wang X; Kong L; Zhao Z; Shi Z; Chen H; Lang Y; Lin X; Du Q; Zhou H
Front Immunol; 2022; 13():953993. PubMed ID: 35958613
[TBL] [Abstract][Full Text] [Related]
13. Myelin-oligodendrocyte glycoprotein antibody-associated disease.
Marignier R; Hacohen Y; Cobo-Calvo A; Pröbstel AK; Aktas O; Alexopoulos H; Amato MP; Asgari N; Banwell B; Bennett J; Brilot F; Capobianco M; Chitnis T; Ciccarelli O; Deiva K; De Sèze J; Fujihara K; Jacob A; Kim HJ; Kleiter I; Lassmann H; Leite MI; Linington C; Meinl E; Palace J; Paul F; Petzold A; Pittock S; Reindl M; Sato DK; Selmaj K; Siva A; Stankoff B; Tintore M; Traboulsee A; Waters P; Waubant E; Weinshenker B; Derfuss T; Vukusic S; Hemmer B
Lancet Neurol; 2021 Sep; 20(9):762-772. PubMed ID: 34418402
[TBL] [Abstract][Full Text] [Related]
14. Effects of immunotherapies and prognostic predictors in neuromyelitis optica spectrum disorder: a prospective cohort study.
Shi Z; Du Q; Chen H; Zhang Y; Qiu Y; Zhao Z; Wang J; Yan C; Zhang Q; Yang M; Zhou H
J Neurol; 2020 Apr; 267(4):913-924. PubMed ID: 31776721
[TBL] [Abstract][Full Text] [Related]
15. Successful disease control with alemtuzumab in MOG-IgG-associated demyelinating disease with MS-phenotype.
Otto F; Moser T; Feige J; Seiberl M; Bieler L; Sellner J
Mult Scler Relat Disord; 2020 Jul; 42():102108. PubMed ID: 32339987
[TBL] [Abstract][Full Text] [Related]
16. Follow-up study on Chinese children with relapsing MOG-IgG-associated central nervous system demyelination.
Zhou J; Lu X; Zhang Y; Ji T; Jin Y; Xu M; Bao X; Zhang Y; Xiong H; Chang X; Jiang Y; Wu Y
Mult Scler Relat Disord; 2019 Feb; 28():4-10. PubMed ID: 30529926
[TBL] [Abstract][Full Text] [Related]
17. Retrospective analysis of children with myelin oligodendrocyte glycoprotein antibody-related disorders.
Konuskan B; Yildirim M; Gocmen R; Okur TD; Polat I; Kilic H; Saltik S; Ozturk Z; Gucuyener K; Altunbasak S; Celik T; Kose G; Yilmaz A; Komur M; Kayilioglu H; Anlar B
Mult Scler Relat Disord; 2018 Nov; 26():1-7. PubMed ID: 30212767
[TBL] [Abstract][Full Text] [Related]
18. Pediatric myelin oligodendrocyte glycoprotein antibody-associated disease in southern China: analysis of 93 cases.
Li X; Wu W; Hou C; Zeng Y; Wu W; Chen L; Liao Y; Zhu H; Tian Y; Peng B; Zheng K; Shi K; Li Y; Gao Y; Zhang Y; Lin H; Chen WX
Front Immunol; 2023; 14():1162647. PubMed ID: 37342342
[TBL] [Abstract][Full Text] [Related]
19. Persistent MOG-IgG positivity is a predictor of recurrence in MOG-IgG-associated optic neuritis, encephalitis and myelitis.
Oliveira LM; Apóstolos-Pereira SL; Pitombeira MS; Bruel Torretta PH; Callegaro D; Sato DK
Mult Scler; 2019 Dec; 25(14):1907-1914. PubMed ID: 30417715
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of immunotherapies in relapsing myelin oligodendrocyte glycoprotein antibody-associated disease.
Bilodeau PA; Vishnevetsky A; Molazadeh N; Lotan I; Anderson M; Romanow G; Salky R; Healy BC; Matiello M; Chitnis T; Levy M
Mult Scler; 2024 Mar; 30(3):357-368. PubMed ID: 38314479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
